<DOC>
	<DOC>NCT00483392</DOC>
	<brief_summary>The purpose of this study is to evaluate and compare the effects of treatment with rosiglitazone and metformin on insulin resistance in patients infected with Human Immunodeficiency Virus on stable Highly Active Antiretroviral Therapy including a Protease Inhibitor after the period of 48 weeks.</brief_summary>
	<brief_title>Treatment of Hyperglycaemia and Insulin Resistance in HIV Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>documented HIV infection stable Protease Inhibitor containing HAART regimen for at least 12 months impaired glucose tolerance elevated insulin levels (above 20 mIU/l) patients already taking oral hypoglycaemic treatment or insulin heart failure NYHA IIV liver disease or kidney disease elevated AST or ALT above 2 times upper normal range elevated creatinine (above 150 mmol/l)</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>insulin</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>metformin</keyword>
	<keyword>hiv</keyword>
	<keyword>protease inhibitors</keyword>
</DOC>